|
Sleep, Diabetic Retinopathy and Melatonin
RECRUITINGPhase 2Sponsored by University of Illinois at Chicago
Actively Recruiting
PhasePhase 2
SponsorUniversity of Illinois at Chicago
Started2021-02-03
Est. completion2025-12
Eligibility
Age40 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT04547439
Summary
This study explores the use of melatonin in patients with diabetic retinopathy
Eligibility
Age: 40 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria: * Type 2 diabetes (clinically diagnosed, taking anti-diabetes medications or history of elevated A1C≥6.5%) * 40-65 years of age * Diabetic retinopathy of at least moderate degree Exclusion Criteria: * use of melatonin * antidepressants or antipsychotics * illicit drug use * night shift work or travel beyond 2 time zones in the month before enrollment * end stage renal disease requiring renal replacement therapy * history of stroke or transient ischemic attacks * history of dementia or memory impairment * uncontrolled congestive heart failure or recent hospitalization for cardiac condition (6 months) * chronic obstructive pulmonary disease requiring oxygen * severe chronic liver disease such as cirrhosis * ongoing treatment for major medical problems such as cancer * history of severe hypoglycemia defined as hypoglycemic episodes requiring assistance from others within the past six months. * Significant depressive symptoms * untreated severe OSA (AHI≥ 30 events/hour), * uncontrolled hypertension (blood pressure ≥ 160/100 mmHg), * uncontrolled diabetes (A1C ≥ 11%), * abnormal TSH * abnormal liver function (AST or ALT\>3x upper limits of normal * use of sedatives and hypnotics. * clinically significant epiretinal membranes, clinically significant lens opacities, or cystoid macular edema, iris neovascularization, iris atrophy, or an asymmetrically shaped pupil, nuclear sclerotic, posterior subcapsular, or cortical lens opacities greater than 2+, a history of pan-retinal photocoagulation. * hemoglobin \<11.5 g/dL in women and \<13.5 g/dL in men.
Conditions3
DiabetesDiabetes MellitusDiabetic Retinopathy
Locations1 site
University of Illinois at Chicago
Chicago, Illinois, 60612
Sirimon Reutrakul, MD
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorUniversity of Illinois at Chicago
Started2021-02-03
Est. completion2025-12
Eligibility
Age40 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT04547439